224 institutions reported holding VRDN for 2026Q1, together 110% of the company, fewer than the 228 a quarter earlier. Institutions reporting a position: 224 (as of 2026Q1). Shares held by institutions: 112.4M, long US equity positions only, as reported on Form 13F. Reported value: $2.21B, at 2026-03-31 prices, not today's. Top 5 holders: 40%, of the whole company, between five filers.

VRDNViridian Therapeutics, Inc.

HealthcareUSD

$24.25

$13.3052 weeks$33.78

Who owns VRDN

224 institutions reported holding VRDN for 2026Q1, together 110% of the company, fewer than the 228 a quarter earlier.

224

Institutions reporting a position · as of 2026Q1 · down from 228 the quarter before

Shares held by institutions: 112.4M
Shares held by institutions · 110% of the company · long US equity positions only, as reported on Form 13F
Reported value: $2.21B
Reported value · at 2026-03-31 prices, not today's
Top 5 holders: 40%
Top 5 holders · of the whole company, between five filers

Details›

Reporting quarter2026-03-31: 2026Q1
Quarters on record: 22
New positions: 42
Positions exited: 50
Added to: 78
Reduced: 66
Top 10 holdersof the company: 57%

Institutional ownership by quarter, 2020Q4 to 2026Q1
Quarter	Filers	Shares	Reported value
2026Q1	224	112.4M	$2.21B
2025Q4	228	107.8M	$3.35B
2025Q3	168	93.2M	$2.01B
2025Q2	169	94.5M	$1.32B
2025Q1	176	91.4M	$1.23B
2024Q4	178	91.0M	$1.75B
2024Q3	165	87.0M	$1.98B
2024Q2	138	69.6M	$906M
2024Q1	136	71.0M	$1.24B
2023Q4	132	60.1M	$1.31B
2023Q3	123	50.2M	$769M
2023Q2	127	47.1M	$1.12B
2023Q1	134	43.1M	$1.10B
2022Q4	122	41.2M	$1.21B
2022Q3	105	38.0M	$778M
2022Q2	84	28.3M	$328M

Largest reported holders, 2026Q1
Holder	Shares	% of company	Value
FMR LLC	15.4M	15%	$301M
BlackRock Inc.	7.8M	7.6%	$153M
Bellevue Group AG	6.7M	6.6%	$132M
VANGUARD GROUP INC	6.5M	6.3%	$127M
STATE STREET CORP	4.7M	4.6%	$91M
Fairmount Funds Management LLC	3.9M	3.8%	$77M
Venrock Adviser, LLC	3.9M	3.8%	$76M
PRICE T ROWE ASSOCIATES INC /MD/	3.2M	3.1%	$63M
Paradigm Biocapital Advisors LP	3.1M	3.1%	$62M
WELLINGTON MANAGEMENT GROUP LLP	3.1M	3.0%	$60M

SEC Form 13F data sets (DERA bulk files). 13F is quarterly, filed up to 45 days late, and covers long US equity positions only, no shorts, no derivatives, nothing held below the reporting threshold.

reading the register…

Biotechnology

Ranks #127 of 145 by Smart Score

Compare peers

SION+4.1%

Sionna Therapeutics, Inc.

LKFT-0.59%

Lakefront Biotherapeutics NV

STOK+0.03%

Stoke Therapeutics, Inc.

PVLA+4.9%

Palvella Therapeutics, Inc.

IOVA-0.94%

Iovance Biotherapeutics, Inc.

MESO-6.8%

Mesoblast Limited